These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30863706)

  • 1. Ribosomal maturation factor (RimP) is essential for survival of nontuberculous mycobacteria
    Poonam ; Yennamalli RM; Bisht GS; Shrivastava R
    3 Biotech; 2019 Apr; 9(4):127. PubMed ID: 30863706
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Katoch P; Bisht GS; Shrivastava R
    Int J Mycobacteriol; 2019; 8(4):390-396. PubMed ID: 31793511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of the Type-II Fatty acid synthase gene
    Sharma A; Vashistt J; Shrivastava R
    Int J Mycobacteriol; 2022; 11(2):159-166. PubMed ID: 35775548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Random insertion transposon mutagenesis of Mycobacterium fortuitum identified mutant defective in biofilm formation.
    Katoch P; Gupta K; Yennamalli RM; Vashistt J; Bisht GS; Shrivastava R
    Biochem Biophys Res Commun; 2020 Jan; 521(4):991-996. PubMed ID: 31727369
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Pang Y; Zheng H; Tan Y; Song Y; Zhao Y
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing disulfiram to target infections caused by non-tuberculous mycobacteria.
    Das S; Garg T; Chopra S; Dasgupta A
    J Antimicrob Chemother; 2019 May; 74(5):1317-1322. PubMed ID: 30753528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ribosomal maturation factor P from
    Chu T; Weng X; Law COK; Kong HK; Lau J; Li S; Pham HQ; Wang R; Zhang L; Kao RYT; Lau KF; Ngo JCK; Lau TCK
    J Biol Chem; 2019 Jan; 294(1):372-378. PubMed ID: 30409901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A transposon insertion mutant of Mycobacterium fortuitum attenuated in virulence and persistence in a murine infection model that is complemented by Rv3291c of Mycobacterium tuberculosis.
    Parti RP; Shrivastava R; Srivastava S; Subramanian AR; Roy R; Srivastava BS; Srivastava R
    Microb Pathog; 2008; 45(5-6):370-6. PubMed ID: 18930129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycobacterium fortuitum fabG4 knockdown studies: Implication as pellicle and biofilm specific drug target.
    Sharma A; Vashistt J; Shrivastava R
    J Basic Microbiol; 2022 Dec; 62(12):1504-1513. PubMed ID: 35736669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Speed-Oligo Mycobacteria assay for the identification of nontuberculous mycobacteria.
    Ramis IB; Cnockaert M; Von Groll A; Mathys V; Simon A; Tortoli E; Palomino JC; Almeida da Silva PE; Vandamme P; Andre E; Martin A
    J Med Microbiol; 2015 Mar; 64(Pt 3):283-287. PubMed ID: 25596120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Frequency and clinical relevance of rapidly growing mycobacterium isolated from respiratory samples].
    Duan HF; Wang QF; Wang J; Wang J; Huang HR; Chu NH
    Zhonghua Jie He He Hu Xi Za Zhi; 2016 Feb; 39(2):113-6. PubMed ID: 26879615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination.
    Lee MR; Yang CY; Shu CC; Lin CK; Wen YF; Lee SW; Ko JC; Wang JY; Lee LN; Yu CJ
    Clin Microbiol Infect; 2015 Mar; 21(3):250.e1-7. PubMed ID: 25658545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative proteomic investigation unravels the pathobiology of Mycobacterium fortuitum biofilm.
    Sharma A; Bansal S; Kumari N; Vashistt J; Shrivastava R
    Appl Microbiol Biotechnol; 2023 Oct; 107(19):6029-6046. PubMed ID: 37542577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan.
    Hatakeyama S; Ohama Y; Okazaki M; Nukui Y; Moriya K
    BMC Infect Dis; 2017 Mar; 17(1):197. PubMed ID: 28270102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real time PCR for the rapid identification and drug susceptibility of Mycobacteria present in Bronchial washings.
    Keerthirathne TP; Magana-Arachchi DN; Madegedara D; Sooriyapathirana SS
    BMC Infect Dis; 2016 Oct; 16(1):607. PubMed ID: 27782812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic resistance in
    Jayasingam SD; Zin T; Ngeow YF
    Int J Mycobacteriol; 2017; 6(4):387-390. PubMed ID: 29171453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
    Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
    Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report.
    Erber J; Weidlich S; Tschaikowsky T; Rothe K; Schmid RM; Schneider J; Spinner CD
    BMC Infect Dis; 2020 May; 20(1):365. PubMed ID: 32448204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment.
    Abshire R; Cockrum P; Crider J; Schlech B
    Clin Ther; 2004 Feb; 26(2):191-6. PubMed ID: 15038942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of Mycobacterium fortuitum pulmonary infection presenting with migratory infiltrates: a case report with microbiological analysis.
    Okamori S; Asakura T; Nishimura T; Tamizu E; Ishii M; Yoshida M; Fukano H; Hayashi Y; Fujita M; Hoshino Y; Betsuyaku T; Hasegawa N
    BMC Infect Dis; 2018 Jan; 18(1):1. PubMed ID: 29291713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.